Neurocrine Biosciences Reports Fourth Quarter and Fiscal 202

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ...

Related Keywords

California , United States , San Diego , Neurocrine Biosciences , Sosei Heptares , Neurocrine Bioscience , Kevin Gorman , Neurocrine Biosciences Inc , Sosei Group Corporation , Linkedin , Mitsubishi Tanabe Pharma Corporation , Takeda Pharmaceutical Company , Nasdaq , Xenon Pharmaceuticals , Idorsia Pharmaceuticals , Chief Executive Officer , Months Ended December , Product Sales , Commercial Highlights , Process Research , Expense Guidance , Future Milestones , Key Activities , Huntington Disease , Supplemental New Drug Application , Second Half , Line Registrational Data , Selectivet Type Ca Channel Blocker , Line Phase , Pediatric Epilepsy , Psychiatric Indication , Adrenal Hyperplasia , Major Depressive Disorder , Onset Seizure , Vesicular Monoamine Transporter , Calcium Channel , Epileptic Encephalopathy , Continuous Spike , Wave During Sleep , Corticotropin Releasing Factor Type , Isoxazole Propionic Acid , Orphang Protein Coupled Receptor , Sodium Channel , Bioscience Partners , East Asia , Takeda Pharmaceutical Company Limited , Webcast Today , Quarterly Report ,